Donanemab in Early Symptomatic Alzheimer Disease
 

JAMA. Published online July 17, 2023. doi:10.1001/jama.2023.13239
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial | Dementia and Cognitive Impairment | JAMA | JAMA Network

Original Investigation
July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease
The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
________________
Seems as if there's positive conclusions.

Also noted the conflict in interest disclosures and funding and support.

So far looks promising however. I hope so